Novavax, Inc. (NASDAQ:NVAX) Director Rachel K. King Sells 4,150 Shares

Novavax, Inc. (NASDAQ:NVAX) Director Rachel K. King sold 4,150 shares of the firm’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $9.02, for a total transaction of $37,433.00. Following the sale, the director now owns 14,770 shares in the company, valued at approximately $133,225.40. This trade represents a 21.93 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Novavax Trading Up 6.6 %

NASDAQ NVAX opened at $8.57 on Friday. The firm has a market cap of $1.37 billion, a PE ratio of -3.79 and a beta of 2.02. Novavax, Inc. has a 1-year low of $3.53 and a 1-year high of $23.86. The stock has a 50-day moving average of $8.71 and a 200-day moving average of $11.38.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.07. The company had revenue of $84.51 million during the quarter, compared to the consensus estimate of $65.80 million. During the same quarter in the previous year, the firm posted ($1.26) EPS. The business’s revenue for the quarter was down 54.8% compared to the same quarter last year. As a group, equities research analysts forecast that Novavax, Inc. will post -1.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Novavax

Institutional investors have recently added to or reduced their stakes in the company. Banque Cantonale Vaudoise increased its position in shares of Novavax by 500.0% in the second quarter. Banque Cantonale Vaudoise now owns 3,000 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 2,500 shares during the period. Amalgamated Bank increased its holdings in Novavax by 26.9% during the 2nd quarter. Amalgamated Bank now owns 4,887 shares of the biopharmaceutical company’s stock valued at $62,000 after purchasing an additional 1,036 shares during the period. Signaturefd LLC raised its position in Novavax by 214.5% during the 2nd quarter. Signaturefd LLC now owns 5,680 shares of the biopharmaceutical company’s stock valued at $72,000 after purchasing an additional 3,874 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Novavax by 38.1% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,790 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 1,598 shares during the period. Finally, Midland Wealth Advisors LLC bought a new stake in shares of Novavax in the 2nd quarter worth approximately $152,000. Hedge funds and other institutional investors own 53.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Jefferies Financial Group lowered their price target on Novavax from $31.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, October 16th. HC Wainwright reissued a “buy” rating and set a $19.00 price objective on shares of Novavax in a report on Tuesday, December 10th. Finally, B. Riley reaffirmed a “buy” rating and issued a $26.00 target price (up previously from $23.00) on shares of Novavax in a research note on Thursday, October 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Novavax currently has an average rating of “Hold” and an average price target of $17.83.

Novavax Company Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.